Integrating omics technologies for natural product antibiotic discovery
Lead Participant:
DEMURIS LIMITED
Abstract
Antibiotic discovery from natural sources is beset by the re-isolation of known compounds and the difficulties
in working with wild-type strains. Demuris and TGAC will transform this approach and use genome sequencing
to identify and dereplicate known antibiotic gene clusters from a set of high value actinomycete strains that
produce broad-spectrum antibiotics though presently unknown. Known and novel gene clusters will be
identified bioinformatically and software developed to allow the integration data facilitating cluster
prioritisation. To confirm the bioinformatic predictions the masses of the most promising novel antibiotics will
be identifed and the gene clusters cloned and heterologously expressed using an optimised host. This "data
first" based approach promises to reinvigorate the natural products sector, and this is desperately needed if
new and novel antibiotics are to be developed.
in working with wild-type strains. Demuris and TGAC will transform this approach and use genome sequencing
to identify and dereplicate known antibiotic gene clusters from a set of high value actinomycete strains that
produce broad-spectrum antibiotics though presently unknown. Known and novel gene clusters will be
identified bioinformatically and software developed to allow the integration data facilitating cluster
prioritisation. To confirm the bioinformatic predictions the masses of the most promising novel antibiotics will
be identifed and the gene clusters cloned and heterologously expressed using an optimised host. This "data
first" based approach promises to reinvigorate the natural products sector, and this is desperately needed if
new and novel antibiotics are to be developed.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
DEMURIS LIMITED | £106,767 | £ 74,737 |
  | ||
Participant |
||
EARLHAM INSTITUTE | £43,106 | £ 43,106 |
People |
ORCID iD |